Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers
Phase of Trial: Phase III
Latest Information Update: 17 May 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ANVIL
- 07 Dec 2017 Planned primary completion date changed from 31 May 2018 to 1 Jul 2024.
- 06 Jun 2017 Trial design of the study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 12 Jul 2016 Status changed from not yet recruiting to recruiting.